Quest Diagnostics
DGX
227.06
-1.33
-0.58%
Quest Diagnostics
US · DGX
#767 by market cap
Listed 1996
227.06
-1.33
-0.58%
Live - 5344 symbols - heartbeat 471s ago
· 2026-10-08 07:39
Pre-market
226.30
-0.33%
After-hours
227.06
0.00%
- Market cap
- 25.06B
- P/E (TTM)i
- 24.10
- P/Bi
- 3.33
- EPSi
- 8.75
- Div yieldi
- 1.08%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on DGX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 97.55% -0.26pp
- Institutions
- 1,309 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund81.94%
Public Company5.34%
Hedge Fund3.90%
Private Company1.99%
Government Pension Fund1.64%
Sovereign Wealth Fund1.33%
Family Office/Trust0.50%
Insurance Company0.45%
Individual/Insider0.36%
Other2.55%
Top holders as of 2026-06-30
BlackRock
8.40% · 9.28M sh
Vanguard Capital Management, LLC
7.12% · 7.86M sh
Vanguard Portfolio Management, LLC
5.55% · 6.13M sh
State Street Global Advisors
5.00% · 5.52M sh
T. Rowe Price Group, Inc.
4.92% · 5.43M sh
Boston Partners Global Investors, Inc.
4.30% · 4.74M sh
Geode Capital Management, LLC
2.84% · 3.14M sh
J.P. Morgan Asset Management, Inc.
2.79% · 3.08M sh
EdgePoint Investment Group Inc.
2.04% · 2.25M sh
Dimensional Fund Advisors
1.80% · 1.99M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| James Davis | Chairperson & CEO | 0.11% |
| Catherine Doherty | Senior Vice President of Regional Businesses | 0.06% |
| Michael Prevoznik | General Counsel | 0.04% |
| Michael Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 0.03% |
| Sam Samad | Chief Financial Officer | 0.03% |
| Timothy Main | Independent Director | 0.02% |
| Vicky Gregg | Independent Director | 0.02% |
| Karthik Kuppusamy | Senior Vice President of Clinical Solutions | 0.01% |
| Patrick Plewman | Senior Vice President of Diagnostic Services | 0.01% |
| Mark Delaney | Chief Commercial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Timothy Wentworth | Director | Other Derivative Acquisition | +135 | -- |
| 2026-08-31 | James Davis | Chairperson & CEO | Automatic Disposition | -10,000 | $242.72 |
| 2026-08-27 | Michael Prevoznik | General Counsel | Other Disposition | -1,000 | -- |
| 2026-08-27 | Michael Prevoznik | General Counsel | Derivative Exercise and Sale | -22,677 | $112.17–244.51 |
| 2026-07-27 | Mark Delaney | Chief Commercial Officer | Automatic Disposition | -1,600 | $235.18 |
| 2026-07-21 | Patrick Plewman | Senior Vice President of Diagnostic Services | Other Acquisition | +46 | $206.81 |
| 2026-07-21 | Timothy Main | Independent Director | Other Acquisition | +21 | $206.81 |
| 2026-07-21 | Robert Carter | Director | Other Acquisition | +11 | $206.80 |
| 2026-07-21 | Vicky Gregg | Independent Director | Other Acquisition | +72 | $206.81 |
| 2026-07-21 | Wright Lassiter | Independent Director | Other Acquisition | +6 | $206.81 |
| 2026-07-21 | Sam Samad | Chief Financial Officer | Other Acquisition | +102 | $206.81 |
| 2026-07-21 | Mark Delaney | Chief Commercial Officer | Other Acquisition | +34 | $206.81 |
| 2026-07-21 | Karthik Kuppusamy | Senior Vice President of Clinical Solutions | Other Acquisition | +37 | $206.81 |
| 2026-06-30 | Timothy Wentworth | Director | Other Derivative Acquisition | +144 | -- |
| 2026-06-03 | Karthik Kuppusamy | Senior Vice President of Clinical Solutions | Derivative Exercise and Sale | -8,147 | $121.81–200.00 |
| 2026-05-31 | James Davis | Chairperson & CEO | Automatic Disposition | -10,000 | $194.14 |
| 2026-05-19 | Timothy Main | Independent Director | Other Acquisition | +1,142 | -- |
| 2026-05-19 | Robert Carter | Director | Other Acquisition | +1,142 | -- |
| 2026-05-19 | Timothy Ring | Lead Independent Director | Other Acquisition | +1,142 | -- |
| 2026-05-19 | Gary Pfeiffer | Independent Director | Other Acquisition | +1,142 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:39:48 · For reference only, not investment advice and not tailored to your situation.